AddLife AB
STO:ALIF B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
89.3353
168
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
AddLife AB
AddLife AB
Cash & Cash Equivalents
AddLife AB
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AddLife AB
STO:ALIF B
|
Cash & Cash Equivalents
kr272m
|
CAGR 3-Years
8%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Cash & Cash Equivalents
kr861m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Cash & Cash Equivalents
kr370m
|
CAGR 3-Years
1%
|
CAGR 5-Years
23%
|
CAGR 10-Years
17%
|
|
|
G
|
Genovis AB
STO:GENO
|
Cash & Cash Equivalents
kr135.8m
|
CAGR 3-Years
48%
|
CAGR 5-Years
72%
|
CAGR 10-Years
41%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Cash & Cash Equivalents
kr287.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
76%
|
CAGR 10-Years
15%
|
|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
Cash & Cash Equivalents
kr7.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
AddLife AB
Glance View
AddLife AB engages in the ownership and acquisition of companies in niche segments under the healthcare sector. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2015-03-16. The firm markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The firm operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The firm operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
See Also
What is AddLife AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
272m
SEK
Based on the financial report for Dec 31, 2023, AddLife AB's Cash & Cash Equivalents amounts to 272m SEK.
What is AddLife AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
35%
Over the last year, the Cash & Cash Equivalents growth was -28%. The average annual Cash & Cash Equivalents growth rates for AddLife AB have been 8% over the past three years , 35% over the past five years .
You don't have any saved screeners yet
